Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (DE:ZEGA)
FRANKFURT:ZEGA
ZEGA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€57.50 - €74.00
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
$204.14B
Enterprise Value€243.71B
Total Cash (Recent Filing)$7.11B
Total Debt (Recent Filing)$32.84B
Price to Earnings (P/E)26.6
Beta0.54
Next Earnings
Nov 06, 2025EPS Estimate
0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding3,101,386,000
10 Day Avg. Volume0
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)4.98
Price to Sales (P/S)3.76
P/FCF Ratio27.92
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue5.68
Enterprise Value/Gross Profit7.04
Enterprise Value/Ebitda18.07
Forecast
1Y Price Target
$76.49Price Target Upside19.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Company GrowthManagement remains confident in their $80bn target for 2030, highlighting a combined >$10bn opportunity from readouts across 2025.
Market OpportunityAn increased probability of success for baxdrostat has been reflected in models, projecting significant future revenue.
Trial ResultsBaxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure compared with placebo.
Bears Say
Clinical Trial ChallengesThe clinical program evaluating anselamimab did not achieve statistical significance in the overall population for the primary endpoint.
Product PerformancePerformance across non-oncology products were mixed, with some products below consensus.
AstraZeneca News
ZEGA FAQ
What was Astrazeneca Plc’s price range in the past 12 months?
Astrazeneca Plc lowest stock price was €57.50 and its highest was €74.00 in the past 12 months.
What is Astrazeneca Plc’s market cap?
Astrazeneca Plc’s market cap is $204.14B.
When is Astrazeneca Plc’s upcoming earnings report date?
Astrazeneca Plc’s upcoming earnings report date is Nov 06, 2025 which is in 41 days.
How were Astrazeneca Plc’s earnings last quarter?
Astrazeneca Plc released its earnings results on Jul 29, 2025. The company reported €0.925 earnings per share for the quarter, beating the consensus estimate of €0.921 by €0.004.
Is Astrazeneca Plc overvalued?
According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued.
Does Astrazeneca Plc pay dividends?
Astrazeneca Plc does not currently pay dividends.
What is Astrazeneca Plc’s EPS estimate?
Astrazeneca Plc’s EPS estimate is 0.98.
How many shares outstanding does Astrazeneca Plc have?
Astrazeneca Plc has 3,101,386,000 shares outstanding.
What happened to Astrazeneca Plc’s price movement after its last earnings report?
Astrazeneca Plc reported an EPS of €0.925 in its last earnings report, beating expectations of €0.921. Following the earnings report the stock price went up 1.639%.
Which hedge fund is a major shareholder of Astrazeneca Plc?
Currently, no hedge funds are holding shares in DE:ZEGA
AstraZeneca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$76.49 (19.51% Upside)
$76.49 (19.51% Upside)
Blogger Sentiment
Bullish
DE:ZEGA Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.54%
12-Months-Change
Fundamentals
Return on Equity
19.76%
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
Astrazeneca Plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
ZEGA Company Deck
ZEGA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AstraZeneca demonstrated strong financial performance and significant pipeline advancements, particularly in oncology and biopharmaceuticals. However, challenges remain with Medicare Part D redesign, biosimilar competition, and specific pipeline setbacks.View all DE:ZEGA earnings summariesZEGA Stock 12 Month Forecast
Average Price Target
€76.49
▲(19.51% Upside)
Technical Analysis
Options Prices
Currently, No data available
---